This comprises AML patients with CEBPA mutations or with suppressed CEBPA function because of t(8,21) or inv(16) chromosome aberrations (Pabst et al, 2001a, 2001b; Helbling et al, 2005). This evidence concerns the gene CEBPA and acute myeloid leukemia.